PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: DNAC) is a clinical-stage biopharmaceutical company developing autologous cell-based therapies for chronic kidney disease, with a focus on patients with type 2 diabetes-related kidney decline. The company entered public markets through a SPAC business combination that closed in 2022, placing it in the healthcare and biotechnology sector. ProKidney filed an 8-K current report with the SEC on May 29, 2026, continuing its regular disclosure obligations as a post-combination public company. The filing carries accession number 0001193125-26-248210. For complete filing history, SPAC transaction details, and real-time SEC disclosure tracking on ProKidney and hundreds of other SPACs, sign up for full data on SpacDesk.